Prof. Jinghui Bai 白静慧
Chief Physician, Professor
Department of Medical Oncology, Liaoning Cancer Hospital & Institute, Shenyang
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Chemotherapy, targeted therapy, and integrated care for lung, breast, and gastrointestinal cancers. Research focuses on cancer patients with concurrent cardiovascular disease.
Dr. Bai is Chief Physician, Professor, and Director of the VIP Comprehensive Internal Medicine Ward at Liaoning Cancer Hospital & Institute. Holding a medical doctorate, Dr. Bai serves as a master’s supervisor at China Medical University. With over ten years of clinical experience, Dr. Bai leads provincial-level research projects and has published in SCI and national core journals.
Professional roles
- Chair, Geriatric Oncology Professional Committee, Liaoning Anti-Cancer Association
- Vice Chair, Cancer Rehabilitation and Palliative Care Committee, Liaoning Anti-Cancer Association
- Council Member, Integrated Traditional Chinese and Western Medicine Branch, China Association of Gerontology
- Deputy Editor-in-Chief, Clinical Practical Oncology
Name order: in Chinese the family name comes first (Bai Jinghui). Papers usually list the name as Jinghui Bai or Bai J.
Selected publications
19 papers on PubMed matched by name and affiliation; 6 as first or senior author since 2016. Most recent first- or senior-author papers:
- Rev Cardiovasc Med, 2021 (senior author): Effects of alirocumab on cardiovascular events and all-cause mortality: a systematic review and meta-analysis. PubMed 34565085
- J Cell Physiol, 2020 (first author): lncRNA SNHG1 cooperated with miR-497/miR-195-5p to modify epithelial-mesenchymal transition underlying colorectal cancer exacerbation. PubMed 31276207
- Cell Transplant, 2020 (first author): Ganoderma lucidum Polysaccharide Enzymatic Hydrolysate Suppresses the Growth of Human Colon Cancer Cells via Inducing Apoptosis. PubMed 32495637
- Hum Cell, 2020 (first author): LncRNA NBR2 suppresses migration and invasion of colorectal cancer cells by downregulating miRNA-21. PubMed 31571148
- Oncotarget, 2017 (senior author): Knockdown of miR-27a sensitizes colorectal cancer stem cells to TRAIL by promoting the formation of Apaf-1-caspase-9 complex. PubMed 28423356
- Tumour Biol, 2017 (senior author): Mir-30d suppresses cell proliferation of colon cancer cells by inhibiting cell autophagy and promoting cell apoptosis. PubMed 28651493
- Int J Clin Exp Med, 2015 (senior author): Protective effects of heparin on endothelial cells in sepsis. PubMed 26131136
- Int J Clin Exp Pathol, 2015 (first author): miR-205 regulates A549 cells proliferation by targeting PTEN. PubMed 25973003
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion